LSM5

Across TCGA pan-cancer cohorts, LSM5 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LSM5 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LSM5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated LSM5 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where LSM5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	0.866	0.300	.007	12	view →
HNSC	OS	Median	All	0.449	1.000	.023	6	view →
PDAC	OS	Median	IV	0.491	0.836	.024	3	view →
GBM	DFS	Tertile	All	0.387	0.262	.031	2	view →
CCRCC	OS	Quartile	All	0.934	0.766	.027	2	view →
LSCC	OS	Tertile	All	0.857	0.642	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LSM5–LUAD (OS)

Open the LUAD breakdown →